Laaksonen, H
Guerreiro-Cacais, A O
Adzemovic, M Z
Parsa, R
Zeitelhofer, M
Jagodic, M
Olsson, T
Article History
Received: 21 April 2014
Revised: 19 May 2014
Accepted: 21 May 2014
First Online: 10 July 2014
Competing interests
: Dr Olsson has received personal compensation from Biogen Idec, Merck, Novartis, TEVA, Sanofi-aventis, Genzyme, Almirall, Actelion as member of scientific advisory boards, steering committees or independent data monitoring boards in clinical trials, or as speaker at meetings. His research unit has received unrestricted multiple sclerosis research support from Biogen Idec, Bayer Schering, Merck, Sanofi-aventis, Novartis, the Swedish Research Council, Knut and Alice Wallenbergs Foundation, the AFA Foundation and the Swedish Brain Foundation. The remaining authors declare no conflict of interest.